The Mouse Gene Development Initiative (R01) | Apply Online

Frequently Asked Questions (FAQs)

What is the Mouse Gene Development Initiative (R01)?

The Mouse Gene Development Initiative (R01) is an NIH funding opportunity (RFA-DA-09-015) focused on improving understanding of how genes and environment work together across development to shape addiction-related traits in mice. The initiative emphasizes developmental timing and environmental context, aiming to explain why the same genetic risk factor can lead to different outcomes depending on when exposures occur and under what conditions.

What is the main scientific goal of this funding opportunity?

The central goal is to move beyond studying single genes in isolation and instead examine how genetic background, developmental stage, and environmental exposures combine to influence measurable behaviors and biological outcomes relevant to substance use and addiction.

What kinds of studies are encouraged under this announcement?

The announcement encourages well-designed mouse studies that test gene-by-environment interactions across developmental stages and that generate addiction-relevant behavioral and neurobiological outcomes. Projects are expected to use controlled environmental manipulations and appropriate mouse genetic resources to clarify developmental mechanisms that contribute to addiction vulnerability and related traits.

What are the two major categories of responsive projects?

Projects responsive to this announcement generally fall into two categories: (1) mapping addiction-related traits by systematically varying environmental factors at different developmental stages across multiple inbred mouse strains, and (2) modifier discovery studies that identify epigenetic and genetic modifiers that change phenotypic outcomes under different environmental and developmental conditions in mice carrying a defined genetic variant.

What does "mapping addiction-related traits" mean in this initiative?

In this initiative, mapping refers to studying addiction-relevant traits by varying environmental factors across development and across multiple inbred mouse strains, with the goal of linking differences in outcomes to genetic background and identifying genetic factors associated with those outcomes.

What types of environmental factors does the FOA suggest varying?

Examples of environmental factors mentioned include stress, enrichment, diet, drug exposure timing, maternal care, and other experimentally controlled environments. The emphasis is on systematically varying such factors across developmental stages to see how they interact with genetics to shape addiction-relevant phenotypes.

Which developmental stages are specifically relevant for these studies?

The announcement highlights developmental timing and gives examples of stages including prenatal, juvenile, adolescent, and adult periods. Applicants may design studies that compare effects across these stages to determine when exposures have different consequences.

What kinds of addiction-relevant outcomes or phenotypes are in scope?

Examples of addiction-relevant phenotypes mentioned include drug preference, consumption, withdrawal, sensitivity, relapse-like behavior, and related neurobiological traits. Studies may focus on measurable behaviors and biological outcomes tied to substance use and addiction.

What mouse genetic resources and strategies are encouraged for mapping studies?

The FOA encourages leveraging established genetic resources and strategies such as selective breeding approaches, recombinant inbred lines, the Collaborative Cross, and haplotype-based association mapping using panels of inbred strains.

What is meant by "modifier discovery" in this initiative?

Modifier discovery refers to identifying additional epigenetic or genetic factors that change the phenotypic outcome of a defined genetic variant under different developmental and environmental conditions. The goal is to explain variability and penetrance by uncovering loci, epigenetic states, or regulatory mechanisms that amplify, buffer, or redirect the effects of a specific variant.

What types of defined genetic variants are mentioned for modifier studies?

The FOA mentions models such as knockouts and copy number variants (CNVs), where the primary variant is known but the phenotype can differ depending on background strain, developmental timing, or environmental exposure.

Why does the initiative emphasize background strain and environmental context?

The initiative is designed to address why risk alleles or genetic variants do not produce uniform outcomes. By testing genetic background (strain), developmental stage, and environment together, studies can reveal how context reshapes pathways linked to addiction vulnerability and why outcomes vary across individuals or conditions.

What is the funding mechanism for this opportunity?

The award mechanism is the NIH R01 research project grant, described as the standard mechanism for investigator-initiated, multi-year research projects with defined aims and substantial experimental scope.

Which NIH institutes are involved or highlighted?

The announcement highlights NIDA (National Institute on Drug Abuse) as a primary funder and notes specific interests from NIAAA (National Institute on Alcohol Abuse and Alcoholism) within the announcement's objectives and scope.

Does the scope include both drug abuse and alcohol research?

Yes. The overall theme spans both drug abuse and alcohol research, reflected in the CFDA program areas listed for Alcohol Research Programs (93.273) and Drug Abuse and Addiction Research Programs (93.279).

How much funding was set aside and how many awards were expected?

NIDA set aside approximately 2.0 million dollars in Fiscal Year 2009 and expected to fund roughly 2 to 5 applications. NIAAA indicated an intent to commit about 1 million dollars in total costs to support an additional 2 to 3 new grants in response to the FOA.

What does the stated funding level suggest about the type of projects sought?

Based on the description, the program was designed to fund a small number of relatively substantial projects rather than many smaller exploratory studies. The announcement emphasizes strong experimental rigor, appropriate mouse resources, and clear relevance to addiction-related phenotypes.

Who was eligible to apply?

Eligibility was broad and included many types of domestic and non-domestic applicants. Eligible organizations included public and private institutions of higher education, nonprofit organizations with or without 501(c)(3) status, small businesses, for-profit entities (including those other than small businesses), and a range of government entities.

Which government entities were listed as eligible?

Eligible government entities included state and local governments (including counties, cities, townships, special districts), public housing authorities, independent school districts, tribal governments and tribal organizations (including federally recognized entities), and U.S. territories or possessions. Eligible federal agencies were also referenced.

Were foreign (non-U.S.) organizations eligible?

Yes. The eligibility information explicitly included foreign organizations among eligible applicants.

Did the eligibility language reference specific institution types often targeted for inclusion?

Yes. The eligibility information explicitly referenced Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and faith-based or community-based organizations, among others.

When was the opportunity posted, and what were the key dates?

The opportunity was posted on October 20, 2008. The application closing date was January 27, 2009. The announcement was later archived on February 27, 2009.

Who is the funding agency for this opportunity?

The funding agency is the National Institutes of Health (NIH), and the full announcement was made available through the NIH grants website.

What is the core idea that differentiates this initiative from single-gene studies?

The initiative explicitly aims to move beyond studying single genes in isolation. Instead, it prioritizes designs that test how genetic background, developmental stage, and environmental exposures combine to influence addiction-relevant behaviors and biological outcomes, including situations where the same genetic risk factor leads to different results depending on timing and context.